Substance Use Disorders Recently, a research area has been actively developing related to the potential use of GLP-1RAs in the treatment of addiction diseases, primarily from psychoactive substances, including alcohol dependence
On the dealmaking front, J&J acquired Halda Therapeutics in a $3.05 billion deal that includes Haldas Riptac cell-death platform and its lead candidate HLD-0915, an oral small-molecule therapy targeting metastatic castration-resistant prostate cancer (mCRPC), along with additional RIPTAC-based programs for other solid tumors
Elevated glucagon-like peptide-1 (GLP-1) levels following surgery trigger excessive insulin secretion, leading to reactive hypoglycaemia
Unlock solutions with a local weight loss doctor to evaluate treatment plans suited to your needs
Were you aware of the difference between these 2 supplements
Arm-level data were extracted from primary publications and supplementary materials